September 2012 Editor's Picks: Products from Uhlmann Packaging Systems and GE Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

September 2012 Editor's Picks: Products from Uhlmann Packaging Systems and GE Healthcare

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Uhlmann Packaging Systems
Integrated blister and carton module features simplified changeover

Uhlmann Packaging Systems’ Blister Express Center 500 (BEC 500) is a double-lane, integrated blister and carton module that can process up to 500 blisters and 500 cartons per minute, which makes it ideal for packaging medium-sized batches of standard, solid-dose products. The flexible machine is available with rotary or platen sealing and can produce complex shapes, rigid aluminum pockets, calendar packs, and other nontraditional packages. Between runs, the machine features a newly simplified changeover process that allows a single person to completely reset the entire line in just 30 minutes without the use of tools. Uhlmann’s new SmartControl operating system offers step-by-step guidance through the entire format changeover.


GE Healthcare
Modular, prefabricated bioprocessing facility reduces construction time and capital investment compared to traditional facilities


GE Healthcare’s KUBio modular, 1200-m2 bioprocessing facility is prefabricated and delivered with a complete, ready-to-use production line that is based on GE Healthcare’s Ready-to-Process single-use technologies. The total planning, delivery, and construction time of the facility is 14–18 months, which is significantly less than the 24–36 months needed for traditional construction. Capital investment is also significantly reduced.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Equipment and Processing Report,
Click here